MAPK3 and ovarian carcinoma: Moreover, it has been proven that MEL activates the death receptors and inhibits the JAK2L/STAT3 pathway, leading to the inhibition of ovarian cancer cell growth [44]; it can also decrease the expression levels of p-AKT and ERK1/2, and suppress the Rac1-dependent pathway [45].